35 completed, 5 terminated, 3 recruiting, 2 unknown. 47 Phase 1, 22 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 47 | Completed 35, Terminated 5, Recruiting 3, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 22 | Completed 17, Terminated 2, Unknown 2, Not yet recruiting 1 |
Follow End Stage Renal Disease: new trials by email Literature Review of End Stage Renal Disease trials Research Report on End Stage Renal Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis Bupropion Hydrochloride 150 MG - End Stage Renal Disease, Fatigue | Phase 1 / Phase 2 | Not yet recruiting | The University of Texas Health Science Center at San Antonio | 16 | 2027-02-01 | 2026-11-02 |
| Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease ChoironeX GalKO Porcine Thymokidney - End Stage Renal Disease | Phase 1 | Recruiting | Xeno Holdings (US), LLC dba ChoironeX | 4 | 2026-10-01 | 2026-11-02 |
| A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide Ribupatide - End Stage Renal Disease, Renal Impairment | Phase 1 | Recruiting | Kailera | 32 | 2026-09-08 | 2026-10-01 |
| Initial Safety Study of the TRUE AVC in Hemodialysis Access (TRUE AVC I Study) Arteriovenous conduit implant - End Stage Renal Disease | Phase 1 / Phase 2 | Completed | Vascudyne, Inc. | 11 | 2022-10-04 | 2025-07-03 |
| To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants. AZD8233 - End Stage Renal Disease | Phase 1 | Terminated | AstraZeneca | 3 | 2022-08-10 | 2022-12-22 |
| A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021) Belzutifan - End Stage Renal Disease, Renal Impairment | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2022-07-12 | 2025-04-06 |
| Preliminary Safety of The TRUE Vascular Graft for Hemodialysis Access (TRUE HD I Study) natural human collagen arteriovenous graft for hemodialysis access - End Stage Renal Disease | Phase 1 | Completed | Vascudyne, Inc. | 10 | 2021-05-10 | 2022-06-23 |
| Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients TX200-TR101 - Kidney Transplant Rejection, End Stage Renal Disease | Phase 1 / Phase 2 | Completed | Sangamo Therapeutics | 26 | 2021-03-17 | 2026-07-02 |
| Berinert (C1INH) vs Placebo for DGF/IRI Berinert, Placebo - End Stage Renal Disease, Chronic Kidney Diseases | Phase 1 / Phase 2 | Completed | Cedars-Sinai Medical Center | 45 | 2021-03-03 | 2024-12-04 |
| Plazomicin Study in ESRD Patients Receiving IHD Plazomicin Injection - End Stage Renal Disease | Phase 1 | Completed | Cipla USA Inc. | 6 | 2021-01-05 | 2022-03-09 |
| Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus. Triferic - End Stage Renal Disease | Phase 1 / Phase 2 | Completed | Rockwell Medical Technologies, Inc. | 23 | 2020-06-25 | 2021-07-13 |
| AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses Adipose Derived Mesenchymal Stem Cells - End Stage Renal Disease | Phase 1 | Recruiting | Houssam Farres, M.D. | 15 | 2020-05-15 | 2026-07-10 |
| A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients Triferic, Heparin - End Stage Renal Disease | Phase 1 / Phase 2 | Completed | Rockwell Medical Technologies, Inc. | 12 | 2019-09-30 | 2020-12-02 |
| A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function Tirzepatide - Renal Insufficiency, End Stage Renal Disease | Phase 1 | Completed | Eli Lilly and Company | 45 | 2018-03-30 | 2023-03-23 |
| Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients Triferic - End Stage Renal Disease | Phase 1 / Phase 2 | Completed | Rockwell Medical Technologies, Inc. | 27 | 2017-10-01 | 2020-11-16 |
| The Feasibility of Propofol TCI in Hemodialysis Patients Undergoing Arteriovenous Shunt Surgery Propofol, Sevoflurane - End Stage Renal Disease, Hemodialysis Complication | Phase 1 | Completed | Kaohsiung Medical University Chung-Ho Memorial Hospital | 47 | 2017-09-11 | 2021-09-05 |
| Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients Zepatier, Mavyret - End Stage Renal Disease | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 62 | 2016-05-01 | 2023-06-15 |
| Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients Triferic - End Stage Renal Disease | Phase 1 | Completed | Rockwell Medical Technologies, Inc. | 13 | 2016-04-01 | 2019-02-01 |
| Triferic Pediatric Pharmacokinetic Protocol Triferic - End Stage Renal Disease | Phase 1 / Phase 2 | Completed | Rockwell Medical Technologies, Inc. | 22 | 2015-11-01 | 2018-10-25 |
| Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers Triferic - End Stage Renal Disease | Phase 1 | Completed | Rockwell Medical Technologies, Inc. | 12 | 2015-10-01 | 2019-08-20 |
Showing 20 of 47. Sign in to see all of them.
Kidney Failure, Chronic (47) · Renal Insufficiency (7) · Renal Insufficiency, Chronic (4) · Kidney Diseases (3) · Anemia (2) · Delayed Graft Function (1) · Disorders of Excessive Somnolence (1) · End Stage Liver Disease (1) · Fatigue (1) · Hyperphosphatemia (1) · Multiple Myeloma (1) · Obesity (1) · Overweight (1) · Substance-Related Disorders (1)
Chronic Disease (47) · Disease Attributes (47) · Female Urogenital Diseases (47) · Female Urogenital Diseases and Pregnancy Complications (47) · Male Urogenital Diseases (47) · Pathologic Processes (47) · Pathological Conditions, Signs and Symptoms (47) · Urogenital Diseases (47) · Urologic Diseases (47) · Kidney Diseases (44) · Renal Insufficiency, Chronic (43) · Renal Insufficiency (40) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Mental Disorders (2)
ferric pyrophosphate (6) · spleen fibrinolytic proteinase (human) (6) · Antilymphocyte Serum (2) · Complement C1 Inhibitor Protein (2) · Mycophenolic Acid (2) · Rituximab (2) · Saline Solution (2) · Bupropion (1) · Chocolate (1) · Cyclophosphamide (1) · Cyclosporine (1) · Droxidopa (1) · Heparin (1) · Kidney Transplantation (1) · NOX-H94 (1)
Rockwell Medical Technologies, Inc. (6) · Cedars-Sinai Medical Center (2) · Massachusetts General Hospital (2) · Vascudyne, Inc. (2) · Aevi Genomic Medicine, LLC, a Cerecor company (1) · Arkansas Children's Hospital Research Institute (1) · AstraZeneca (1) · Bristol-Myers Squibb (1) · Chelsea Therapeutics (1) · Christoph Aufricht (1) · Cipla USA Inc. (1) · Cumberland Pharmaceuticals (1) · Eli Lilly and Company (1) · Emory University (1) · Hoffmann-La Roche (1)
United States (32) · Germany (3) · Australia (2) · Poland (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Israel (1) · Italy (1) · Netherlands (1) · New Zealand (1) · Panama (1) · Paraguay (1) · Taiwan (1)
Raymond D Pratt, MD FACP (2) · A. Benedict Cosimi, M.D. (1) · Adrian Ebner, MD (1) · Anh Nyugen, MD (1) · Anton Skaro, MD (1) · Ashley Vo, PharmD (1) · Christoph Aufricht, Univ.Prof.Dr. (1) · Christopher Haqq, MD, PhD (1) · David Sachs, M.D. (1) · Deborah Haller (1) · Doron Schwartz, Professor (1)
PMID 19822798, PMID 21714604, PMID 22457244, PMID 22657252, PMID 26331581, PMID 26485680, PMID 30083748, PMID 30704882, PMID 30957581, PMID 33778934, PMID 37916745, PMID 40349965, PMID 40972903
2009 (1), 2019 (1), R01NR004340 (1)